|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, higher incidence of repeat revascularization after PCI in diabetic AMI patients a major concern until recently.
|
31420948 |
2020 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transitional health management effectively improved adherence in elderly patients with acute myocardial infarction after PCI, ameliorated clinical indicators, and effectively reduced the incidence of adverse cardiovascular events and readmission rates.
|
31150451 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Databases were searched for studies comparing MV-PCI and CL-PCI in patients with AMI and CS.
|
30593731 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that FKN@day-1 is negative correlated with myocardial salvage after acute myocardial infarction and might be a valuable prognostic marker of MACE in patients with STEMI undergone PCI.
|
30352758 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
First-line treatment for AMI is to reperfuse the occluded coronary artery by PCI as soon as possible.
|
30484228 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients free from ischaemic heart disease at baseline and subsequently hospitalised with AMI or angina, Cox regression was used to model the association between distress (Kessler-10 scores: low [10-<12], mild [12-<16], moderate [16-<22] and high [22-50]) - assessed on the questionnaire - and coronary angiography and revascularisation procedures (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) within 30 days of admission, adjusting for personal characteristics, including physical functioning.
|
31445320 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) demonstrated superiority of routine early coronary angiography (and percutaneous coronary intervention [PCI]) compared with standard therapy in fibrinolytic-treated patients with ST-segment elevation myocardial infarction (STEMI) at 30 days.
|
29801739 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiovascular death, acute myocardial infarction (AMI), or PCI at 1year was assessed using multivariate logistic regression analysis.
|
29220755 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this prospective observational study, patients with LVEF ≥40% who underwent PCI within 7 days following AMI were enrolled to receive an ICM.
|
28069838 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the fHb concentrations increased between 12 and 48 hours after PCI in patients with AMI.
|
30116144 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of atrial fibrillation on complications and prognosis of patients receiving emergency PCI after acute myocardial infarction.
|
30233710 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medical literature databases were screened to identify analyses comparing MV-PCI with C-PCI in patients with cardiogenic shock complicating acute myocardial infarction and multivessel coronary artery disease.
|
28703046 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regarding shock, preliminary data suggests that a concept of early left ventricular unloading before PCI maybe the critical factor for improving the outcome for acute myocardial infarction complicating myocardial infarction.
|
28856523 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
And OR values of AMI patients in the before and after PCI subgroup were 0.43 (95% CI 0.21-0.91, p = 0.03) and 1.36 (95% CI 0.76-2.41, p = 0.30).
|
29167607 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
84 cases of patients with combined AMI and CS under PCI in emergency treatment were randomly divided into the control group (n=42) and observational group (n=42).
|
28682422 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Likewise, considered are physiological metrics fractional flow reserve, coronary flow reserve, index of microvascular resistance (FFR, CFR, IMR) obtained from invasive studies performed in the cardiac catheterization laboratory, typically at the time of PCI for MI.
|
28577226 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our analysis shows that in patients with AMI undergoing PCI, GLP-1 treatment is associated with improved LVEF and reduced infarct size.
|
28286967 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Rationale:</b> Microembolization during PCI for acute myocardial infarction can cause microvascular obstruction <b>(MVO)</b>.
|
28912893 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bivalirudin lead to statistical reduction on bleeding risks in comparison to heparin plus tirofiban, and only small numerical difference in comparison to heparin, with comparable risks of ischemic events and stent thrombosis in patients with acute myocardial infarction (AMI) undergoing emergency transradial PCI.
|
27677411 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
From 1995 to 2013, 4,078 consecutive patients underwent primary PCI for AMI.
|
27884422 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty-two patients with AMI successfully treated with primary PCI underwent cardiovascular magnetic resonance after 4-6 days and 3 months.
|
28644903 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exclusion criteria included PCI for acute myocardial infarction, in-stent restenosis, chronic total occlusion, left main, and saphenous vein graft lesions.
|
28112479 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with AMI underwent reperfusion therapy (percutaneous cardiac intervention [PCI] or thrombolytic therapy) or conservative drug therapy.
|
23771713 |
2013 |